|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 29, 26777-26783, July 20, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, January 17, 2001, and in revised form, May 9, 2001
To investigate the cellular functions
of sulfated glycosphingolipids, we introduced the cerebroside
sulfotransferase (CST) gene into J5 cells, a subclone of 3LL Lewis lung
carcinoma cells. The J5 cells lack acidic glycosphingolipids but
accumulate their common biosynthetic precursor, lactosylceramide. We
established the stable CST transfectants, J5/CST-1 and J5/CST-2 clones,
highly expressing sulfated lactosylceramide (SM3). Both clones
exhibited more spherical morphology in comparison to mock transfectant, and their adhesiveness to fibronectin and laminin was significantly lower. The loss of cell-substratum interactions in these SM3-expressing cells could be attributed to decreased expression of integrins ( Sulfatides are biosynthesized from the acceptor substrates,
glycosphingolipids (GSLs),1
and the sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate, by the
action of cerebroside sulfotransferase (CST, EC 2.8.2.11) (1).
CST transfers the sulfate group to the 3-position of the galactose in
lactosylceramide (LacCer) and galactosylceramide (GalCer) and forms
galactosylsulfatide (SM4) and lactosylsulfatide (SM3), respectively
(2). CST did not show sulfotransferase activity toward the
oligosaccharides that had been used as substrates in the previous
studies on the glycoprotein The physiological functions of sulfatides have long been noted for
their unique property of having a strong negative electronic charge in
the molecule. Sulfatides interact with various biomolecules especially
in cell adhesion, differentiation, and signal transduction (reviewed in
Refs. 5 and 6). In the case of cell-substratum adhesion, SM4 and SM3
have been found to bind several proteins such as laminin and
thrombospondin (7). When exogenous SM4 was incorporated into SMKT-R3
cells (human renal cell carcinoma), their attachment to laminin, but
not to fibronectin, was enhanced (8). However, it was uncertain whether
the data obtained from these experiments truly reflect the cellular
functions of endogenous sulfatides.
The purpose of the present study was to investigate the functional role
of endogenous sulfatide in cell adhesion. We employed a subclone of the
mouse 3LL Lewis lung carcinoma cell line, 3LL-J5, which has high LacCer
content but no galactosylceramide and SM3 (9, 10), to introduce the
recently cloned CST gene (1). The stable CST transfectants expressing
SM3 at a high level exhibited decreased adhesive abilities to both
fibronectin and laminin. We demonstrated here an inverse (or negative)
relationship between the level of cellular SM3 and cell adhesive
ability as well as tumorigenicity.
Materials--
For the GSL analysis, DEAE-Sephadex A-25 was
purchased from Amersham Pharmacia Biotech, and Sep-Pak C18
and silica gel HPTLC plates were from Waters Associates (Milford, MA)
and Merck, respectively. pcDNA3.1/Zeo(+) and zeocin were from
Invitrogen (Carlsbad, CA), and LipofectAMINE PLUSTM Reagent was
from Life Technologies, Inc. Human fibronectin and mouse laminin were
from Biomedical Technologies Inc. (Stoughton, MA). A cell counting kit
based on a modified 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide method was employed (Dojindo, Kumamoto, Japan). For flow
cytometry, anti- Cell Line and Culture Conditions--
A subclone of the murine
3LL Lewis lung carcinoma cell line, J5, was described previously (9).
Cells were maintained in RPMI 1640 medium (Nissui, Tokyo, Japan)
containing 10% (v/v) fetal calf serum (Sigma), 100 units/ml
penicillin, 100 ng/ml streptomycin, 9.4% (v/v) sodium bicarbonate, and
100 mM L-glutamine. Cells were cultured in a
humidified, 5% CO2 atmosphere tissue culture incubator and
passaged every 3 days using a trypsin/EDTA (0.1% and 1 mM) solution. Transfected and mock-transfected cells were cultured in the
above medium containing also 300 µg/ml zeocin (Invitrogen).
CST Expression Vector Transfection--
J5 cells were
transfected using LipofectAMINE PLUSTM Reagent with plasmid
pcDNA3.1/Zeo(+)-hCST prepared with human sulfotransferase cDNA
(1) integrated into the expression vector pcDNA3.1/Zeo(+). The
hCST-transfected cells were primarily selected in the same medium used
for growing them. As a control for transfection, mock cells were
prepared with pcDNA3.1/Zeo(+) without hCST cDNA.
Semi-quantitative RT-PCR--
Total RNA was isolated from
cultured cells using the Trizol reagent, and one-step RT-PCR was
performed using the mixture of reverse transcriptase and Taq
DNA polymerase (Life Technologies, Inc.) according to the
manufacturer's instructions. The RNA was reverse-transcribed at
45 °C for 30 min, and the cycling conditions were 94 °C for 2 min, followed by 25 cycles of 94 °C for 0.15 min, 50 °C for 0.5 min, and 72 °C for 2 min. The following primer pairs were used:
glyceraldehyde-3-phosphate dehydrogenase, forward 5'ACCACAGTCCATGCCATCAC3' and reverse 5'TCCACCACCCTGTTGCTGTA3' (product size 451 bp); mouse integrin Northern Blot Analysis--
Total RNA (10 µg) from cells was
denatured in 50% formamide, 6% formaldehyde, 20 mM MOPS
(pH 7.0) at 65 °C, electrophoresed on 1% agarose gel containing 6%
formaldehyde, blotted onto a nylon membrane (Roche Molecular
Biochemicals), and cross-linked by UV irradiation. A
digoxigenin-labeled RNA probe for CST mRNA was synthesized from the
XhoI fragment of pBS-hCST1 (1) using a DIG RNA labeling kit
with T7 RNA polymerase (Roche Molecular Biochemicals) according to the
manufacturer's instructions. A digoxigenin-labeled RNA probe for mouse
Sulfotransferase Assay--
Cells cultured in a 100-mm dish were
scraped off and washed three times with PBS. The cells were resuspended
in 300 µl of Tris-buffered saline (pH 7.4) containing 0.1% Triton
X-100 and homogenized by sonication on ice. The protein concentration
was adjusted to 1 mg/ml. CST activity was assayed in 30 µl of a
mixture containing 25 mM sodium cacodylate (pH 6.4), 50 µM GalCer in 5% Triton X-100, 10 mM
MnCl2, 1% Lubrol PX, 0.25 mM dithiothreitol, 5 mM NaF, 2 mM ATP, 50 mM NaCl, and
40 µM [35S]3'phosphoadenosine
5'-phosphosulfate, plus 20 µl of the enzyme source. This was
incubated for 30 min at 37 °C, and then 1 ml of
chloroform/methanol/water (30:60:8) was added. The mixture was applied
to a DEAE-Sephadex A-25 column (Amersham Pharmacia Biotech) that was
then washed with 2 ml each of chloroform/methanol/water (30:60:8) and
methanol. [35S]Sulfatide was eluted with 8 ml of 90 mM AcONH4 in methanol directly into a
scintillation vial. The radioactivity was determined in 10 ml of
scintillation fluid by a liquid scintillation spectrometer (Amersham
Pharmacia Biotech, type 1211).
Lipid Analysis--
The total lipids were extracted from the
cells with chloroform/methanol/water (4:4:0.3 and 2:4:0.3),
successively. The combined extracts were then applied to a
DEAE-Sephadex A-25 column (acetate form, 2.4-ml bed volume), and the
neutral lipids were eluted with 12 ml of chloroform/methanol/water
(30:60:8). The acidic lipid fraction was then eluted with 12 ml of
chloroform/methanol/aqueous 0.8 M sodium acetate (30:60:8).
The neutral and acidic lipid fractions were evaporated to dryness, and
contaminating esters were methanolyzed with methanolic 0.1 M NaOH for 1 h at 40 °C. The solution was neutralized with 1 M acetic acid in methanol, diluted with
an equal volume of aqueous 50 mM NaCl, and applied to a
Sep-Pak C18 reverse-phase cartridge. The cartridge was
washed with 40 ml of water, and lipids were eluted with 10 ml of
methanol and 10 ml of chloroform/methanol (1:1), successively. The
eluate was evaporated to dryness, and the lipids were analyzed by
HPTLC. The plates were then developed with chloroform/methanol/aqueous
12 mM magnesium chloride (60:25:4, for neutral lipids) or
chloroform/methanol/water (65:25:4, for acidic lipids). Glycolipids
were visualized by spraying orcinol reagent and heating at 100 °C
for 10 min and then quantified with a dual-wavelength flying spot
scanner (CS9300-PC, Shimadzu, Kyoto, Japan) in the reflectance mode at
500 nm with integrated areas.
Immunological Detection of SM4 and SM3--
TLC immunoblotting
was performed by the method of Taki et al. (12), slightly
modified as follows. Acidic lipids were separated on an HPTLC plate
with chloroform/methanol/water (65:25:4) and then immersed in a mixture
of isopropyl alcohol/aqueous 0.2% calcium chloride/methanol
(40:20:7) for 20 s. The plate was then covered with a
polyvinylidene difluoride (PVDF) membrane (Immobilon, Millipore, Bedford, MA) and a glass microfiber filter (Atto Instruments, Tokyo,
Japan). This was then pressed (level 8) for 50 s with TLC Thermal
Blotter (Atto Instruments) at 180 °C, after which the PVDF membrane
was separated from the plate and dried. The PVDF membrane was agitated
in 5% skim milk/TBS-T (aqueous 137 mM NaCl, 20 mM Tris-HCl (pH 7.5), 0.05% Tween 20) for 1 h, and
then the membrane was shaken in the primary antibody O4 (for galactosyl sulfatide and lactosyl sulfatide) (13) or anti-SM3 (for lactosyl sulfatide) (11) solution in 5% skim milk/TBS-T at 4 °C overnight. The membrane was washed with TBS-T and dipped and shaken in the secondary antibody, peroxidase-conjugated goat anti-mouse IgM, solution
in 5% skim milk/TBS-T for 1 h. After washing with TBS-T, the
membrane was analyzed with an enhanced chemiluminescence system (ECL kit).
Western Blotting of Integrins and Treatment of Endoglycosidase
H--
Subconfluent mock and CST transfectants cells cultured in
75-cm2 culture dishes were rinsed with cold PBS and were
solubilized in SDS-gel sample buffer containing 0.4% SDS, 1%
Flow Cytometry--
Cells were detached from the culture surface
by a 20-min incubation at 37 °C in 10 mM EDTA/PBS,
pelleted, washed with FACS buffer (0.1% BSA and 0.1% NaN3
in PBS) twice, and then resuspended in FACS buffer containing 10 µg/ml anti- Cell Attachment Assay--
100 µl of fibronectin or laminin
(1, 5, 10 and 25 µg/ml) in PBS were added to each well of 96-well
plates, incubated overnight at room temperature, and removed. The
coated wells were further incubated with 100 µl of 0.1% BSA in PBS
at room temperature for 1 h and washed with PBS three times. Each
well was incubated with 50 µl of 0.01% BSA in RPMI 1640 medium at
37 °C for 1 h. A 50-µl suspension of J5/CST-1, J5/CST-2, or
mock cells (5 × 103) in 0.01% BSA/RPMI 1640 was
added to the fibronectin- or laminin-coated wells and incubated for 30 min. Non-adherent cells were removed by inverting the plate, and each
well was gently washed with 100 µl of serum-free RPMI 1640 medium. To
each well were added 100 µl of the same medium followed by 10 µl of
cell counting kit. After incubation at 37 °C for 2 h, the
absorbance (450 nm) of formazan generated in the wells was measured
with a dual-wavelength flying spot scanner (CS9300-PC, Shimadzu, Kyoto,
Japan). The attachment ability was expressed as the percentage of
attached cells (absorbance of attachment cells in the well/absorbance
of total cells added to the well × 100).
Establishment of the Stable CST Transfectants Highly Expressing
SM3--
Previously, we subcloned the J5 clone, which lacked acidic
GSLs and accumulated LacCer, from the wild type of murine 3LL Lewis lung carcinoma cells (9). The CST gene was introduced into the J5 clone
to generate sulfatide-expressing clones. A total of 24 transfectant
clones were finally obtained by limited dilution, and 2 clones
(J5/CST-1 and J5/CST-2) which expressed relatively high levels of CST
gene mRNA (Fig. 1A) and
CST activity (Fig. 1B) were chosen for further study. The
mRNA and the enzyme activity of CST appeared only in the clones
into which the vector constructed with the CST gene had been introduced
but not in the mock-transfected clones (Fig. 1, A and
B). Because the J5 clone expresses only LacCer but not
GalCer (9, 10), introduction of the CST gene into this clone should
express only SM3 as a sulfatide. The GSL fractions were prepared from
mock and J5/CST-1 and -2 cells, and the SM3 content in proportion to
the CST activity was confirmed on HPTLC visualized with orcinol reagent
(Fig. 1C). There was no visible staining of SM4 in both mock
and the CST transfectants.
Analyses of the neutral GSLs of J5/CST-1 and -2 cells showed that not
only the contents of LacCer and its precursor GlcCer were decreased,
but also that of the globo type GSL, Gb3 (Fig. 1C). This
indicated that the biosynthetic pathway from LacCer (at the LacCer
branching point) was greatly shifted to the sulfo type. We further
identified only SM3 but not SM4 by immunoblotting on HPTLC using
anti-SM3 monoclonal antibody (11), which recognizes only SM3, and with
O4 antibody (13), which recognizes both SM4 and SM3 (Fig.
1D). By using the anti-SM3 antibody, strong expression of
SM3 on the cell surface was confirmed by flow cytometry (Fig. 1E). Thus, we designated J5/CST-1 and -2 cells as SM3 high
expressors, and the following experiments were carried out using these
two clones and the mock transfectant.
Comparison of Cell Growth, Morphology and Cell-Substratum
Adhesion--
When in vitro growth of mock and CST
transfectants was compared, there was no difference in the rates of
cell proliferation under the normal culture conditions on plastic
plates (Fig. 2A). On the other
hand, there was a significant increase of the spherical form in the CST
transfectants (Fig. 2B), indicative of weak adhesiveness of
the SM3-expressing cells. Both J5/CST-1 and -2 cells exhibited a marked
decrease in their adhesive abilities to the plastic coated with laminin
and fibronectin (Fig. 3A).
Moreover, the cells highly expressing SM3 were unable to spread on the
surface coated with fibronectin even 2 h after seeding (Fig.
3B).
Decreased Integrin Expression in CST Transfectants--
The
expression of integrin molecules on the cell surface involved in the
recognition of fibronectin ( Selective Decrease of Loss of Tumorigenicity--
Since the tumorigenic and metastatic
potentials of tumors are greatly affected by the expression levels of
integrins (17-20), we were interested in the behavior of the
SM3-expressing cells in vivo. When the mock and the CST
transfectants were inoculated subcutaneously into syngeneic C57/BL6
mice, and then examined for their tumor growth, a remarkable decrease
or even no sign of tumor growth was observed (Fig.
7).
Since no difference in in vitro cell growth in
culture plastic between the mock and the CST transfectants was observed
(Fig. 2A), the loss of tumorigenicity in vivo
could be due to the global loss of integrin functions that are
essential for malignant tumor growth.
LacCer is the common precursor of numerous GSLs consisting
of six groups classified as the ganglio, globo, isoglobo, neolacto, lacto, and sulfo series. Their expression is primarily determined by
cell type-specific expression of enzymes at the lumenal side of Golgi
membranes responsible for either glycosylation (21) or sulfation (22,
23) of branch point LacCer. Since the composition and distribution of
LacCer-derived GSLs are known to be greatly altered during development
and oncogenic transformation (reviewed in Ref. 24), the elucidation of
the biological significance of LacCer branching in various cellular
functions is one of the most important issues of glycobiology. The
cDNAs of the branching enzymes have been extensively cloned
recently (1, 25-30), and it is now possible to clarify the functions
of GSLs utilizing these synthase genes.
As our first trials to study the biology of LacCer branching, we were
able to show the functioning of cellular SM3 in cell-substratum adhesion using genetically manipulated SM3-expressing cells, containing the CST gene in the J5 clone of 3LL Lewis lung carcinoma cells (9).
Significant findings demonstrated here are as follows. 1) The
transfectants expressing SM3 at a relatively high level exhibited
decreased adhesion to both fibronectin and laminin substrata. 2) The
defect in cell adhesion could be attributed to decreased expression of
integrin proteins, including The mechanism by which the CST gene causes the selective decrease of
One could hypothesize the presence of an SM3-binding protein in the
DIMs of 3LL Lewis lung carcinoma cell lines, since the sulfatide-binding proteolipid protein, the rat myelin and lymphocyte protein, has been identified in a detergent-insoluble complex obtained
from oligodendrocytes and Schwann cells (33). The rat myelin and
lymphocyte protein is a member of the tetraspanin membrane protein
(TMP) group. Other TMPs, such as CD9 (35-38), CD53 (39), CD63 (36, 39,
40), CD81 (37, 39), and NAG-2 (41), have been known to associate with
integrins to make functional complexes that might modulate integrin
signaling (42). Since it has been reported recently that association of
integrin and TMP in DIMs is observed under certain conditions (43, 44), sulfated GSLs concentrated in DIMs (32) might influence the integrin-TMP complexes. Further studies are needed to examine these hypotheses.
Many cell types have a large intracellular pre- Since it is known that SM4 and SM3 can directly bind to laminin and
other bioactive molecules under cell-free conditions (7), we initially
expected enhancement of cell adhesion to laminin in the SM3-expressing
J5/CST-1 and -2 cells. However, this expectation was not corroborated
in our cell adhesion assay due to the significant down-regulation of
integrin expression ( Further detailed study will be performed to verify whether or not the
suppressive effect of SM3 on integrin expression is a physiologically
and/or pathologically relevant event in cells originally expressing
SM3, such as renal cell lines (50, 51) and in tissues expressing CST
gene, such as stomach, small intestine, brain, kidney, lung, and testis
(4). We are currently examining the effects of CST gene or antisense
CST gene transfection into various non-transformed and malignant tumor
cells in cell adhesion as well as integrin expression. Since many tumor
cell lines express ganglioside GM3, which is biosynthesized from LacCer
by the action of GM3 synthase (26), it is also interesting to compare
the degrees of the competing GM3 and SM3 expressions.
Integrins have been implicated in the processes of transformation and
differentiation of certain cell types. Transformation of cells to a
malignant state is often accompanied by quantitative changes in
integrin expression and/or alteration of the types of integrins
expressed. For example, Chinese hamster ovary cells deficient in
fibronectin receptor ( We thank Dr. Norman S. Radin (Emeritus Prof.,
University of Michigan) for valuable comments.
*
This work was supported by Grant-in-aid for Scientific
Research on Priority Areas 12033201 (to J. I), by Grant-in-aid for Scientific Research 11672155 (to J. I.) from the Ministry of
Education, Science, Sports, and Culture of Japan, and by the Yamada
Science Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Biomembrane and Biofunctional Chemistry, Graduate School of
Pharmaceutical Sciences, Hokkaido University, Kita-12-Nishi-6, Kita-ku,
Sapporo 060-0812, Japan. Tel.: 81-11-706-3764, Fax: 81-11-706-4986;
E-mail: inokuchi@kinou02.pharm.hokudai.ac.jp.
Published, JBC Papers in Press, May 14, 2001, DOI 10.1074/jbc.M100428200
2
S. Uemura, K. Kabayama, Y. Igarashi, and J. Inokuchi, unpublished observations.
3
K. Kabayama, S. Uemura, A. Ishii, M. Saito, Y. Igarashi, and J. Inokuchi, manuscript in preparation.
The abbreviations used are:
GSLs, glycosphingolipids;
CST, cerebroside sulfotransferase;
SM4, galactosylsulfatide;
SM3, lactosylsulfatide;
DEAE, diethylaminoethyl;
PBS, phosphate-buffered saline;
MHC, major histocompatibility complex;
RT-PCR, reverse transcriptase-polymerase chain reaction;
MOPS, 3-morpholinopropanesulfonic acid;
LacCer, lactosylceramide;
GalCer, galactosylceramide;
HPTLC, high performance TLC;
, DIG,
digoxigenin;
PVDF, polyvinylidene difluoride;
PAGE, polyacrylamide gel
electrophoresis;
FACS, fluorescence-activated cell sorter;
BSA, bovine serum albumin;
GM3, N-acetylneuraminyllactosylceramide;
bp, base pair;
DIMs, detergent-insoluble microdomains;
TMP, tetraspanin membrane protein.
The Ganglioside and glycosphingolipid nomenclatures are in accordance
with Svennerholm (54) and IUPAC-IUBMB recommendations (55, 56).
Suppression of Integrin Expression and Tumorigenicity by
Sulfation of Lactosylceramide in 3LL Lewis Lung Carcinoma Cells*
,
,
, and
¶
Department of Biomembrane and Biofunctional
Chemistry, Graduate School of Pharmaceutical Sciences, Hokkaido
University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo 060-0812 and
the § Department of Biochemistry, Osaka University Medical
School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5,
6, and
1) on the
cell surface and their whole cellular levels. However, the levels of
H-2Kb and H-2Db antigens remained unchanged.
Reverse transcriptase-polymerase chain reaction and Northern blot
analyses for these integrins exhibited significant decrease of
1 gene expression in J5/CST-1 and 2, but there was no
change in the levels of
5 and
6
transcripts. Deglycosylation by endoglycosidase H treatment clearly
demonstrated that the precursor form of
1 integrin,
possessing high mannose oligosaccharide chains, was preferentially
decreased in the CST transfectants. These results demonstrate that
endogenous SM3 negatively regulates
1 integrin
expression at the transcriptional level, and the decrease of
integrin proteins in the CST transfectants was due to the
post-transcriptional modification. We suggest the putative
importance of the intracellular pre-
1 integrin pool for
normal integrin maturation and subsequent function. Although the
rates of cell proliferation in vitro for mock and CST
transfectants were similar, tumorigenicity of J5/CST-1 and -2 cells
inoculated into syngeneic C57/BL6 mice was greatly decreased or even
absent. This was probably due to global loss of the efficient
cell-matrix interactions, which are essential for the development of
malignant tumors in vivo. Thus, we showed the evidence that
cellular SM3 negatively regulates the cell-substratum interaction,
resulting in the loss of tumorigenicity.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Gal-3'-sulfotransferase (3).
Northern blot analysis showed that CST gene is preferentially transcribed in stomach, small intestine, brain, kidney, lung, and
testis, in that order (4).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5 integrin (clone 5H10-27) was from
PharMingen (San Diego, CA); anti-
6 (monoclonal antibody
1378) and -
1 (monoclonal antibody 1997) integrins were
from Chemicon International Inc. (Temecula, CA); anti-SM3 (11) was
from Seikagaku Corp. (Tokyo, Japan); and fluorescein-conjugated
anti-H-2Db and H-2Kb were from Meiji Nyugyo
Corp. (Tokyo, Japan) as the primary antibodies. Fluorescein-conjugated
anti-mouse IgM from Vector Laboratories Inc. (Burlingame, CA) and
fluorescein-conjugated anti-rat IgG as the secondary antibodies were
from Immunotech (Marseille, France). For Western blotting of integrins,
anti-
5 integrin (antibody 1928) and
anti-
1 integrin (monoclonal antibody 1997) were from Chemicon. For the chemiluminescence detection of glycolipids, horseradish peroxidase-conjugated anti-mouse IgM from Jackson ImmunoResearch (West Grove, PA) and the enhanced chemiluminescence system (ECL kit) from Amersham Pharmacia Biotech were used.
Bicinchoninic acid reagent from Pierce was used for protein
determination. All animal experiments were carried out in accordance
with NIH Guide for Care and Use of Laboratories Animals and approved by
the Animal Care and Use Committee in Hokkaido University.
5, forward
5'TCGCCTCGATCTCCTCTCCA3' and reverse 5'CGCTGCAGATAGATGTAGAC3' (product
size 1099 bp); mouse integrin
6, forward
5'GTGAACGTGAGGTGTGTGAAC3' and reverse 5'CGCATGGTATCGGGGAATGC3' (product
size 377 bp); mouse integrin
1, forward
5'GACTTCCGCATTGGCTTTGGC3' and reverse 5'CAAACACGACACCTGCACACG3'
(product size 1205 bp). The concentration ratio of target cDNA
primers to glyceraldehyde-3-phosphate dehydrogenase primers and the PCR
cycle number was optimized for each reaction.
1 integrin mRNA was synthesized from the AvaII fragment of pGEM1-mouse
1 integrin
(kindly provided by Dr. R. O. Hynes) using a DIG RNA labeling kit
with Sp6 RNA polymerase. Mouse
5 integrin mRNA was
synthesized by RT-PCR using RNA derived from mouse B16 melanoma cells
with primers mouse
5 integrin, forward
5'TCGCCTCGATCTCCTCTCCA3' and reverse 5'CGCTGCAGATAGATGTAGAC3' (product
size 1099 bp), and cloned into pGEM-T easy (Promega, Madison, WI). The
plasmid was linearized with XbaI and transcribed with Sp6
RNA polymerase using a DIG RNA labeling kit as above. The membrane was
stained with methylene blue for the detection of 18 S and 28 S rRNA
and then hybridized with the RNA probe at 68 °C. Detection was with
a DIG-Luminescent Detection kit (Roche Molecular Biochemicals).
-mercaptoethanol, and proteinase inhibitors, and the amounts of
protein in all samples were determined using BCA reagent. The equal
amounts of samples were then boiled for 3 min and clarified by
centrifugation for 5 min at 10,000 rpm in a microcentrifuge.
When deglycosylation of high mannose oligosaccharide chains was
performed prior to SDS-PAGE, each denatured sample was further treated
with 1,000 units of endoglycosidase H (EndoHf, BioLabs Inc.
Beverly, MA) for 1 h 37 °C according to the manufacturer's
instructions. Samples were subjected to SDS-PAGE and transferred to
PVDF membranes and blocked with 5% skim milk/TBS-T. The membranes were
incubated with primary antibody (anti-
5 or
anti-
1 integrin), washed, and then incubated with the
appropriate horseradish peroxidase-coupled secondary antibody for 60 min at room temperature. Immunoreactive proteins were visualized by
autoradiography using an enhanced chemiluminescence system (ECL kit).
5,
6,
1
integrin or anti-SM3 for 1 h at 4 °C. For the detection of
whole cellular integrins, cells were permeabilized with 0.1% saponin
containing FACS buffer for 15 min at 4 °C before adding the
appropriate primary antibody. Then the cells were washed with FACS
buffer three times, treated with fluorescein-conjugated anti-rat IgG or
fluorescein-conjugated anti-mouse IgM for 1 h at 4 °C in the
dark, and washed with FACS buffer as above. The intensity of cell
fluorescence was determined by a FACScan cytometer (Becton Dickinson).
For the detection of MHC, cells treated without or with saponin were
stained with 100 µg/ml fluorescein-conjugated anti H-2Db
or H-2Kb in FACS buffer for 1 h at 4 °C and washed
with FACS buffer as above.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (36K):
[in a new window]
Fig. 1.
CST transfection into J5 clone and GSL
analysis. A, Northern blot analyses of CST. Total RNA
samples (10 µg) of J5/CST-1, -2, and mock were electrophoresed,
transblotted onto a nylon membrane, and hybridized with a
digoxigenin-labeled RNA probe of CST, as described under
"Experimental Procedures." Methylene blue staining of 18 S and
28 S rRNA in the samples analyzed above is presented
(bottom). B, CST enzyme activities of J5/CST-1,
-2, and mock were measured in duplicate as described under
"Experimental Procedures." C, GSLs in J5/CST-1, -2, and
mock, corresponding to 1 mg of protein, were applied to an HPTLC plate,
developed, and stained with orcinol-sulfuric acid (acidic GSLs,
left and neutral GSLs, right). D, GSLs
in J5/CST-1, -2, and mock, corresponding to 0.1 mg of protein, were
applied to an, HPTLC plate, developed, transblotted onto a PVDF
membrane, and stained with an anti-SM3 antibody (top) or O4
antibody (bottom), as described. E, cell surface
expression of SM3 by flow cytometry. Mock (top), J5/CST-1
(middle), and J5/CST-2 (bottom) were stained with
an anti-SM3 antibody and fluorescein-conjugated anti-mouse IgM. The
solid line indicates reactivity with anti-SM3; the
dotted line shows secondary antibody alone.

View larger version (41K):
[in a new window]
Fig. 2.
Growth behavior and morphology of CST
transfectants. A, proliferation of CST transfectants.
Five thousands cells of J5/CST-1, -2, and mock were plated in 96-well
plates, and the growth rate of each clone was measured every day up to
4 days by the modified tetrazolium method. B, morphological
differences between mock and CST transfectants. Bar = 100 µm.

View larger version (47K):
[in a new window]
Fig. 3.
Cell adhesion and spreading on laminin and
fibronectin. A, 96-well plates were coated with laminin
and fibronectin, and cell attachment assay was performed as described
under "Experimental Procedures." B, J5/CST-1 and mock
cells were seeded on a plastic plate coated with laminin and
fibronectin at 10 µg/ml, and 2 h later, the plates were washed
with PBS, fixed with 2.5% glutaraldehyde, stained with Giemsa, and
photographed (× 200). Bar = 100 µm.
5 and
1) and
laminin (
6 and
1) was analyzed by flow
cytometry (Table I). All of the integrins
examined here exhibited a marked decrease (around 32-43% in both
J5/CST-1 and -2 cells). After cell permeabilization with saponin,
almost similar decreases in the cellular integrins were observed,
demonstrating that the decreases in cell surface integrins in the SM3
highly expressing cells were due to their decreased cellular contents.
The expression of H-2Kb and H-2Db antigens did
not show significant differences between the mock and the CST
transfectants (Table I). Therefore, the decrease of integrin expression
in the CST transfectants may be a specific cellular event regulated by
cellular SM3. As shown in Fig. 4, the
significant reduction of
5 and
1 proteins
in CST transfectants was observed by Western blot analysis, confirming
the data of flow cytometry (Table I). It has been reported that
cellular integrins, especially
1-subunit, can be
separated into two bands on SDS-PAGE due to the different
oligosaccharide chains on the protein; the lower band has been
designated the precursor form of
1-subunit (high mannose
type) and the upper band is the mature form (complex type) (14, 15). We
also observed two immunoreactive bands in lysates of both mock and CST
transfectants by anti-
1 antibody, and the transition
from the pre-
1 to the maturely glycosylated form
increases the size from ~120 to 130 kDa (Fig. 4A). Removal of immature N-linked glycan chains by digestion with
endoglycosidase H (16) reduced the size to ~80 kDa, whereas the
maturely glycosylated
1 band of ~130 kDa was not
cleaved by endoglycosidase H (Fig. 4A). Thus, the decrease
of
1 integrin protein in CST transfectants was mainly
due to the dramatic decrease of the precursor form (Fig.
4A). The amount of
5 integrin protein in CST
transfectants was decreased to around 50% in comparison to that of
mock transfectant (Fig. 4B). The determination of
6 integrin by Western blotting using two different
anti-
6 antibodies was unsuccessful due to nonspecific
staining. By taking the data from Table I and Fig. 4, we concluded that
the cell surface expression of
5,
6, and
1 integrins as well as their chemical quantities were
decreased in CST transfectants.
Flow cytometric analysis of the amounts of cell surface and total
cellular integrins and H-2 antigens

View larger version (25K):
[in a new window]
Fig. 4.
Decreased cellular integrin contents in CST
transfectants. A, the cell lysates (20 µg of protein)
from mock (lanes 1 and 4), J5/CST1 (lanes
2 and 5), and J5/CST2 (lanes 3 and
6) were subjected to Western blot analysis using
anti-
1 integrin antibody. Endoglycosidase H treatment of
each cell lysate (lanes 4-6) was performed prior to
SDS-PAGE. B, the cell lysates (20 µg of protein) from mock
(lane 1), J5/CST1 (lane 2), and J5/CST2
(lane 3) were subjected to Western blot analysis using
anti-
5 integrin antibody.
1 Integrin mRNA in CST
Transfectants--
We asked here whether the decreased integrin
contents in the CST transfectants originated from the decreased
cellular amounts of their mRNAs themselves. Semi-quantitative
RT-PCR for
5,
6, and
1
integrins showed the selective decrease of
1 gene
expression levels in J5/CST-1 and -2 (Fig.
5). There was no difference between the
mRNA levels of
5 and
6 integrins in
both the mock and CST transfectants at various PCR cycles under
non-saturating conditions, and the representative picture was presented
in Fig. 5. Northern blot analysis clearly indicated the significantly
lowered level of
1 integrin mRNA in both SM3 high
expressing cells, J5/CST-1 and J5/CST-2, but only a slight decrease in
the SM3 low expressing J5/CST-3 cells, showing the inverse relationship
between the levels of cellular SM3 and
1 integrin
mRNA content (Fig. 6, A
versus C). The levels of
5
transcript both in mock and CST transfectants were essentially the same
(Fig. 6B). These results demonstrate the selective
transcriptional down-regulation of
1 integrin by endogenous SM3.

View larger version (23K):
[in a new window]
Fig. 5.
Selective decrease of
1 integrin mRNA in CST
transfectants. Semi-quantitative RT-PCR for
5,
6, and
1 integrins was performed as
described under "Experimental Procedures."

View larger version (52K):
[in a new window]
Fig. 6.
Inverse relationship between the levels of
cellular SM3 and
1 integrin
mRNA. Northern blot analyses of
1 integrin
(A) and
5 integrin (B). Methylene
blue staining of 18 S and 28 S rRNA in the same membrane. Comparison
of SM3 contents among the CST transfectants by HPTLC
(C).

View larger version (19K):
[in a new window]
Fig. 7.
Loss of tumorigenicity in CST
transfectants. Tumors were induced in C57BL/6 mice (8 weeks old,
female) by subcutaneous injection of 2 × 105
cells/0.1 ml in the axillary region by puncture in the inguinal region.
Three weeks later, the tumors were excised and weighed. Mock,
n = 15; J5/CST-1, n = 10; J5/CST-2,
n = 15.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5-,
6-, and
1-subunits, on the cell surface as well as their whole
cellular levels. Although there might be a general decrease of cellular
integrins in the CST transfectants, MHC expression was, however, not
altered significantly, suggesting a selective action of cellular SM3 on
integrin expression. 3) Integrin expression is regulated at both
transcriptional and post-transcriptional levels, since only
1 integrin mRNA but not
5 and
6 mRNAs decreased in SM3-expressing cells. 4)
Although the rates of cell proliferation in vitro were
similar for the mock and the CST transfectants, tumorigenicity of the
SM3-expressing cells in vivo was dramatically lower,
probably due to the global loss of the efficient cell-matrix
interactions in vivo.
1 integrin mRNA remains to be elucidated. Many
cytokines are known to regulate integrin transcription (reviewed in
Ref. 31). The initial signaling cascade of several cytokines may occur
at lipid rafts, which are believed to function as signaling domains in
the plasma membrane (reviewed in Ref. 32). GSLs including sulfatides
are concentrated in the lipid rafts, which can be isolated as the
detergent-insoluble microdomains (DIMs) (33). If the distinctive
organization and functions of lipid rafts from the mock and CST
transfectants can be elucidated, the information might explain the
transcriptional suppression of
integrin. We have obtained
preliminary evidence regarding differences in the protein composition
and patterns of tyrosine-phosphorylated proteins in the two types of
DIMs.2
1
integrin pool in endoplasmic reticulum (45-49) and form

1 heterodimers when they are still located in this
compartment (45). It has been also suggested that the excess of
pre-
1 in endoplasmic reticulum might be required for the
efficient heterodimer formation (47). As demonstrated in Table I and
Figs. 4-6, we observed a significant decrease in the
pre-
1 pool correlated with the reduction of the
1-transcript in the SM3-expressing cells. Although the
protein levels of
5 and
6 integrins were
considerably diminished similar to that of the pre-
1,
the
5- and
6-transcripts remained
unaltered. An interesting hypothesis is that under conditions in which
only a limited number of pre-
1-chains are available, the
-subunits inefficiently form 
1 heterodimers,
thereby leading the enhancement of intracellular degradation of
-subunits before reaching the plasma membranes. In fact, this idea
is supported by our experimental data showing the parallel decreases on
the cell surface expression between
-subunits and
1
integrin in the SM3-expressing cells (Table I). We also observed a
decrease of spontaneous cell motility in CST transfectants (data not
shown). Therefore, we are currently studying the effects of endogenous
SM3 on integrin biosynthesis and recycling by the metabolic labeling
and pulse-chase experiments.
6 and
1 integrins)
which occurred when SM3 was expressed endogenously by CST transfection. In other words, we present the evidence for the first time that endogenous sulfated GSLs, especially SM3, negatively regulate cell-substratum adhesion. If the other anionic GSLs, such as
gangliosides, exhibit similar or opposite effect against cellular SM3,
then our current approach to express SM3 alone by introducing CST gene into the cells lacking all anionic GSLs would be one of the most practical approaches to reveal and identify the functional role of
individual anionic GSL molecule. Interestingly enough, when we
transfected GM3 synthase gene (26) constructed with the same vector
used in this paper into J5 cells to express GM3, the GM3-expressing cells exhibited the ability to attach and spread on fibronectin more
efficiently.3 In contrast to
the SM3-expressing cells,
1 integrin mRNA content was elevated in the GM3-expressing cells. This finding would explain the distinctive roles of sulfation and sialylation on carbohydrates as
well as the significance of GSL function at the LacCer branching point.3
5
1 integrin)
exhibited increased tumorigenicity (52). Overexpression of
5
1 integrin into Chinese hamster ovary
cells led to loss of tumorigenicity (53). On the other hand, increased
expression of
6 integrin, which involves laminin
binding, showed enhanced metastatic potential in Lewis lung carcinoma
cells (17). The
1-subunit associates with at least 10
-subunits (
1-
9 and
v),
constituting the largest subfamily of the integrins. Targeted
disruption of the
1 integrin gene (20) or administration
of anti-
1 antibody (18) greatly reduced metastatic
capacity. Since the CST transfectants obtained here exhibited global
loss of
5,
6, and
1
integrin expression, we were interested in examining their malignancy
in vivo. Surprisingly, tumorigenicity of the SM3-expressing
cells inoculated into syngeneic mice was decreased drastically or even
lost, although there was no difference in vitro cell growth
potential among these clones. Therefore, we assume that the loss of
tumorigenicity might be due to the global loss of the efficient
cell-matrix interactions, which are essential for the development of
malignant tumors in the body. Our findings might open up a new strategy
of gene therapy for malignant and metastatic tumors, if it becomes
possible to transfect human tumors in vivo with the human
CST gene.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Honke, K.,
Tsuda, M.,
Hirahara, Y.,
Ishii, A.,
Makita, A.,
and Wada, Y.
(1997)
J. Biol. Chem.
272,
4864-4868
2.
Honke, K.,
Yamane, M.,
Ishii, A.,
Kobayashi, T.,
and Makita, A.
(1996)
J. Biochem. (Tokyo)
119,
421-427
3.
Honke, K.,
Tsuda, M.,
Koyota, S.,
Wada, Y.,
Iida-Tanaka, N.,
Ishizuka, I.,
Nakayama, J.,
and Taniguchi, N.
(2001)
J. Biol. Chem.
276,
267-274
4.
Hirahara, Y.,
Tsuda, M.,
Wada, Y.,
and Honke, K.
(2000)
Eur. J. Biochem.
267,
1909-1917
5.
Varki, A.
(1993)
Glycobiology
3,
97-130
6.
Ishizuka, I.
(1997)
Prog. Lipid Res.
36,
245-319
7.
Roberts, D. D.,
and Ginsburg, V.
(1988)
Arch. Biochem. Biophys.
267,
405-415
8.
Kobayashi, T.,
Honke, K.,
Kuramitsu, Y.,
Hosokawa, M.,
Miyazaki, T.,
Murata, J.,
Saiki, I.,
Ishizuka, I.,
and Makita, A.
(1994)
Int. J. Cancer
56,
281-285
9.
Inokuchi, J.,
Jimbo, M.,
Kumamoto, Y.,
Shimeno, H.,
and Nagamatsu, A.
(1993)
Clin. Exp. Metastasis
11,
27-36
10.
Inokuchi, J.,
Uemura, S.,
Kabayama, K.,
and Igarashi, Y.
(2000)
Glycoconj. J.
17,
1-7
11.
Hiraiwa, N.,
Fukuda, Y.,
Imura, H.,
Tadano-Aritomi, K.,
Nagai, K.,
Ishizuka, I.,
and Kannagi, R.
(1990)
Cancer Res.
50,
2917-2928
12.
Taki, T.,
Handa, S.,
and Ishikawa, D.
(1994)
Anal. Biochem.
221,
312-316
13.
Sommer, I.,
and Schachner, M.
(1981)
Dev. Biol.
83,
311-327
14.
Jaspers, M.,
de Strooper, B.,
Spaepen, M.,
van Leuven, F.,
David, G.,
van den Berghe, H.,
and Cassiman, J-J.
(1988)
FEBS Lett.
231,
402-406
15.
Akiyama, S.,
Yamada, S. S.,
and Yamada, K. M.
(1989)
J. Biol. Chem.
264,
18011-18018
16.
Kobata, A.
(1979)
Anal. Biochem.
100,
1-14
17.
Sacchi, A.,
Falcioni, R.,
Piaggio, G.,
Gianfelice, M. A.,
Perrotti, N.,
and Kennel, S. J.
(1989)
Cancer Res.
49,
2615-2620
18.
Fujita, S.,
Suzuki, H.,
Kinoshita, M.,
and Hirohashi, S.
(1992)
Jpn. J. Cancer Res.
83,
1317-1326
19.
Gong, J.,
Wang, D.,
Sun, L.,
Zborowska, E.,
Wilson, J. K.,
and Brattain, M. G.
(1997)
Cell Growth Differ.
8,
83-90
20.
Stroeken, P. J.,
van Rijthoven, E. A.,
van der Valk, M. A.,
and Roos, E.
(1998)
Cancer Res.
58,
1569-1577
21.
Colley, K. J.
(1997)
Glycobiology
7,
1-13
22.
Benjamins, J. A.,
Hadden, T.,
and Skoff, R. P.
(1982)
J. Neurochem.
38,
233-241
23.
Tennekoon, G.,
Zaruba, M.,
and Wolinsky, J.
(1983)
J. Cell Biol.
97,
1107-1112
24.
Hakomori, S.
(1981)
Annu. Rev. Biochem.
50,
733-764
25.
Nagata, Y.,
Yamashiro, S.,
Yodoi, J.,
Lloyd, K. O.,
Shiku, H.,
and Furukawa, K.
(1992)
J. Biol. Chem.
267,
12082-12089
26.
Ishii, A.,
Ohta, M.,
Watanabe, Y.,
Matsuda, K.,
Ishiyama, K.,
Sakoe, K.,
Nakamura, M.,
Inokuchi, J.,
Sanai, Y.,
and Saito, M.
(1998)
J. Biol. Chem.
273,
31652-31655
27.
Kojima, Y.,
Fukumoto, S.,
Furukawa, K.,
Okajima, T.,
Wiels, J.,
Yokoyama, K.,
Suzuki, Y.,
Urano, T.,
Ohta, M.,
and Furukawa, K.
(2000)
J. Biol. Chem.
275,
15152-15156
28.
Keusch, J. J.,
Manzella, S. M.,
Nyame, K. A.,
Cummings, R. D.,
and Baenziger, J. U.
(2000)
J. Biol. Chem.
275,
25308-25314
29.
Keusch, J. J.,
Manzella, S. M.,
Nyame, K. A.,
Cummings, R. D.,
and Baenziger, J. U.
(2000)
J. Biol. Chem.
275,
25315-25321
30.
Togayachi, A.,
Akashima, T.,
Ookubo, R.,
Kudo, T.,
Nishihara, S.,
Iwasaki, H.,
Mio, H.,
Inokuchi, J.,
Irimura, T.,
Sasaki, K.,
and Narimatsu, H.
(2001)
J. Biol. Chem.
276,
22032-22040
31.
Kim, L. T.,
and Yamada, K. M.
(1997)
Proc. Soc. Exp. Biol. Med.
214,
123-131
32.
Simons, K.,
and Ikonen, E.
(1997)
Nature
387,
569-572
33.
Brown, D. A.,
and Rose, J. K.
(1992)
Cell
68,
533-544
34.
Frank, M.,
van der Haar, M. E.,
Schaeren-Wiemers, N.,
and Schwab, M. E.
(1998)
J. Neurosci.
18,
4901-4913
35.
Slupsky, J. R.,
Seehafer, J. G.,
Tang, S. C.,
Masellis-Smith, A.,
and Shaw, A. R. E.
(1989)
J. Biol. Chem.
264,
12289-12293
36.
Nakamura, K.,
Iwamoto, R.,
and Mekada, E.
(1995)
J. Cell Biol.
129,
1691-1705
37.
Radford, K. J.,
Thorne, R. F.,
and Hersey, P.
(1996)
Biochem. Biophys. Res. Commun.
222,
13-18
38.
Sheikh-Hamad, D.,
Suki, W. N.,
and Zhao, W.
(1997)
Am. J. Physiol.
273,
C902-C908
39.
Mannion, B. A.,
Berditchevski, F.,
Kraeft, S. K.,
Chen, L. B.,
and Hemler, M. E.
(1996)
J. Immunol.
157,
2039-2047
40.
Berditchevski, F.,
Bazzoni, G.,
and Hemler, M. E.
(1995)
J. Biol. Chem.
270,
17784-17790
41.
Tachibana, I.,
Bodorova, J.,
Berditchevski, F.,
Zutter, M. M.,
and Hemler, M. E.
(1997)
J. Biol. Chem.
272,
29181-29189
42.
Berditchevski, F.,
and Odintsova, E.
(1999)
J. Cell Biol.
146,
477-492
43.
Ono, M.,
Handa, K.,
Withers, D. A.,
and Hakomori, S.
(2000)
Biochem. Biophys. Res. Commun.
279,
744-750
44.
Claas, C.,
Stipp, C. S.,
and Hemler, M. E.
(2001)
J. Biol. Chem.
276,
7974-7984
45.
Heino, J.,
Ignotz, R. A.,
Hemler, M. E.,
Crouse, C.,
and Massague, J.
(1989)
J. Biol. Chem.
264,
380-388
46.
Akiyama, S. K.,
and Yamada, K. M.
(1987)
J. Biol. Chem.
262,
17536-17542
47.
Koivisto, L.,
Heino, J.,
Häkkinen, L.,
and Larjava, H.
(1994)
Biochem. J.
300,
771-779
48.
Lenter, M.,
and Vestweber, D.
(1994)
J. Biol. Chem.
269,
12263-12268
49.
Svinerg, G.,
and Johansson, S.
(1999)
J. Cell Sci.
112,
4751-4761
50.
Kobayashi, T.,
Honke, K.,
Kamio, K.,
Sakakibara, N.,
Gasa, S.,
Miyao, N.,
Tsukamoto, T.,
Ishizuka, I.,
Miyazaki, T.,
and Makita, A.
(1993)
Br. J. Cancer
67,
76-80
51.
Tadano, K.,
and Ishizuka, I.
(1979)
Biochim. Biophys. Acta
575,
421-430
52.
Plantefaber, L. C.,
and Hynes, R. O.
(1989)
Cell
56,
281-290
53.
Giancotti, F. G.,
and Ruoslahti, E.
(1990)
Cell
60,
849-859
54.
Svennerholm, L.
(1980)
Adv. Exp. Biol. Med.
125,
11
55.
IUPAC-IUBMB Joint Commission on Biochemical Nomenclature.
(1997)
Pure Appl. Chem.
69,
2475-2487
56.
IUPAC-IUBMB Joint Commission on Biochemical Nomenclature.
(1998)
Carbohydr. Res.
312,
167-175
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. Qian, E. Georges-Labouesse, A. Nystrom, A. Domogatskaya, K. Tryggvason, S. E. W. Jacobsen, and M. Ekblom Distinct roles of integrins {alpha}6 and {alpha}4 in homing of fetal liver hematopoietic stem and progenitor cells Blood, October 1, 2007; 110(7): 2399 - 2407. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Garcia, N. Callewaert, and L. Borsig P-selectin mediates metastatic progression through binding to sulfatides on tumor cells Glycobiology, February 1, 2007; 17(2): 185 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamashita, Y.-P. Wu, R. Sandhoff, N. Werth, H. Mizukami, J. M. Ellis, J. L. Dupree, R. Geyer, K. Sandhoff, and R. L. Proia Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions PNAS, February 22, 2005; 102(8): 2725 - 2730. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Moro, E. Perlino, E. Marra, L. R. Languino, and M. Greco Regulation of {beta}1C and {beta}1A Integrin Expression in Prostate Carcinoma Cells J. Biol. Chem., January 16, 2004; 279(3): 1692 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uemura, K. Kabayama, M. Noguchi, Y. Igarashi, and J.-i. Inokuchi Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in3LL Lewis lung carcinoma cells Glycobiology, March 1, 2003; 13(3): 207 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sandhoff, S. T. Hepbildikler, R. Jennemann, R. Geyer, V. Gieselmann, R. L. Proia, H. Wiegandt, and H.-J. Grone Kidney Sulfatides in Mouse Models of Inherited Glycosphingolipid Disorders. DETERMINATION BY NANO-ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY J. Biol. Chem., May 31, 2002; 277(23): 20386 - 20398. [Abstract] |